What is Multiple System Atrophy?
Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic nervous system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord.
Multiple System Atrophy Epidemiology
- MSA is an orphan disease with an incidence of up to 2.4 cases per 100 000 persons per year, while the prevalence may reach up to 7.8 patients per 100 000 population over the age of 40.
- MSA appears to affect males and females in equal numbers. The peak onset of MSA is between 55-60 years of age, with a range from 30 to over 90 years.
How will Multiple System Atrophy Market change in the forecast period?
Extensive research and development activities of pharmaceutical companies for developing the therapies will significantly impact Multiple System Atrophy market. Drugs in the clinical trials are expected to propel the growth of the Multiple System Atrophy drugs market in the upcoming years.
Expected launch TD-9855 (Theravance Biopharma), BHV-3241 (Biohaven Pharmaceutical), BIIB101 (Biogen), safinamide (Zambon), CS10BR05 (Corestem), ATH434 (Alterity Therapeutics) and others shall fuel the growth of the market during the forecast period, 2020–2030.
Multiple System Atrophy market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a CAGR of XX during the study period.
For more information on Multiple System Atrophy market trends, request sample pages here @ Multiple System Atrophy market Size
The Multiple System Atrophy (MSA) market report provides current treatment practices, emerging drugs, Multiple System Atrophy (MSA) market share of the individual therapies, current and forecasted Multiple System Atrophy (MSA) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Multiple System Atrophy (MSA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
The Multiple System Atrophy (MSA) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Multiple System Atrophy (MSA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Multiple System Atrophy (MSA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
For more information on Multiple System Atrophy market forecast, request sample pages here @ Multiple System Atrophy market forecast